| __timestamp | Mesoblast Limited | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 25434000 | 179279000 |
| Thursday, January 1, 2015 | 23783000 | 186359000 |
| Friday, January 1, 2016 | 29763000 | 171785000 |
| Sunday, January 1, 2017 | 12065000 | 208136000 |
| Monday, January 1, 2018 | 5508000 | 198405000 |
| Tuesday, January 1, 2019 | 75173000 | 224169000 |
| Wednesday, January 1, 2020 | 81497000 | 245044000 |
| Friday, January 1, 2021 | 85731000 | 252314000 |
| Saturday, January 1, 2022 | 63572000 | 268225000 |
| Sunday, January 1, 2023 | 54922000 | 304629000 |
| Monday, January 1, 2024 | 41070000 | 324203000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. Mesoblast Limited and Taro Pharmaceutical Industries Ltd. offer a fascinating study in contrasts. From 2014 to 2024, Mesoblast's cost of revenue fluctuated significantly, peaking in 2021 with a 237% increase from its 2014 figures. Meanwhile, Taro Pharmaceutical maintained a more stable trajectory, with costs rising steadily by 81% over the same period.
Mesoblast's cost volatility reflects its dynamic business strategies, while Taro's consistent growth underscores its operational stability. Notably, Taro's cost of revenue in 2024 is nearly eight times that of Mesoblast, highlighting its larger scale. This data provides a window into the strategic priorities and market positioning of these two industry players, offering valuable insights for investors and analysts alike.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Zoetis Inc. and Taro Pharmaceutical Industries Ltd.
Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down GSK plc and Mesoblast Limited's Expenses
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Mesoblast Limited
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Mesoblast Limited
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Mesoblast Limited or Taro Pharmaceutical Industries Ltd.: Who Leads in Yearly Revenue?
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Evotec SE